# Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

> **NCT05335876** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 175 (estimated)

## Conditions studied

- Spinal Muscular Atrophy (SMA)

## Interventions

- **BIOLOGICAL:** onasemnogene abeparvovec

## Key facts

- **NCT ID:** NCT05335876
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-19
- **Primary completion:** 2030-09-26
- **Final completion:** 2031-02-27
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335876, "Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05335876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*